GlaxoSmithKline (GSK) has announced full results from the Salford Lung Study (SLS), a pioneering study of COPD treatment aimed at creating a clinical trial much closer to everyday clinical practice.
GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...
Hosted on MSN26d
FDA to review GSK’s Nucala for COPDThe US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary ...
China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...
COPD affects more than 390 million people globally and over 14 million people in the US. GSK noted that recurrent exacerbations add to pressures on healthcare systems, and the COPD -related ...
GSK (GSK) announced the US Food and Drug Administration ... for patients with chronic obstructive pulmonary disease, COPD, with an eosinophilic phenotype. The Prescription Drug User Fee Act ...
Dr. Gur Levy, Respiratory Medical Expert at GSK, said, "We have been pioneering efforts for decades to develop new ...
GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.
GSK’s submission is supported by data from the MATINEE study, which assessed the therapy's safety and efficacy. The study involved 804 COPD patients exhibiting type 2 inflammation, as indicated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback